Literature DB >> 11120987

Effective combination therapy for invasive pneumococcal pneumonia with ampicillin and intravenous immunoglobulins in a mouse model.

L De Hennezel1, F Ramisse, P Binder, G Marchal, J M Alonso.   

Abstract

Intranasal immunotherapy for Streptococcus pneumoniae invasive pneumonia with polyvalent immunoglobulins (IVIG) was effective in mice against pneumonia but failed to prevent bacteremia. The combination of subcurative doses of IVIG and of ampicillin was fully protective. Such an approach, successfully applied in the preantibiotic era, offers new perspectives for modern therapies.

Entities:  

Mesh：

Substances：

Year:  2001        PMID： 11120987      PMCID： PMC90282          DOI： 10.1128/AAC.45.1.316-318.2001

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  28 in total

Review 1.  Molecular and cellular biology of pneumococcal infection.

Authors:  E I Tuomanen; H R Masure
Journal:  Microb Drug Resist       Date:  1997       Impact factor: 3.431

2.  Pneumococcal polysaccharide vaccine in young adults and older bronchitics: determination of IgG responses by ELISA and the effect of adsorption of serum with non-type-specific cell wall polysaccharide.

Authors:  D M Musher; M J Luchi; D A Watson; R Hamilton; R E Baughn
Journal:  J Infect Dis       Date:  1990-04       Impact factor: 5.226

Review 3.  Intranasal antibody prophylaxis for protection against viral disease.

Authors:  R Weltzin; T P Monath
Journal:  Clin Microbiol Rev       Date:  1999-07       Impact factor: 26.132

Review 4.  Clinical uses of intravenous immunoglobulins.

Authors:  S A Berkman; M L Lee; R P Gale
Journal:  Ann Intern Med       Date:  1990-02-15       Impact factor: 25.391

5.  Correlation of opsonophagocytosis and passive protection assays using human anticapsular antibodies in an infant mouse model of bacteremia for Streptococcus pneumoniae.

Authors:  S E Johnson; L Rubin; S Romero-Steiner; J K Dykes; L B Pais; A Rizvi; E Ades; G M Carlone
Journal:  J Infect Dis       Date:  1999-07       Impact factor: 5.226

6.  Streptococcus pneumoniae blood culture isolates from patients with and without human immunodeficiency virus infection: alterations in penicillin susceptibilities and in serogroups or serotypes.

Authors:  H H Crewe-Brown; A S Karstaedt; G L Saunders; M Khoosal; N Jones; A Wasas; K P Klugman
Journal:  Clin Infect Dis       Date:  1997-11       Impact factor: 9.079

Review 7.  Drug-resistant Streptococcus pneumoniae: rational antibiotic choices.

Authors:  M R Jacobs
Journal:  Am J Med       Date:  1999-05-03       Impact factor: 4.965

Review 8.  Multiple antibiotic resistance in Streptococcus pneumoniae.

Authors:  D W Crook; B G Spratt
Journal:  Br Med Bull       Date:  1998       Impact factor: 4.291

9.  Minimum protective serum concentrations of pneumococcal anti-capsular antibodies in infant rats.

Authors:  A M Stack; R Malley; C M Thompson; L Kobzik; G R Siber; R A Saladino
Journal:  J Infect Dis       Date:  1998-04       Impact factor: 5.226

Review 10.  Using monoclonal antibodies to prevent mucosal transmission of epidemic infectious diseases.

Authors:  L Zeitlin; R A Cone; K J Whaley
Journal:  Emerg Infect Dis       Date:  1999 Jan-Feb       Impact factor: 6.883
View more
  10 in total

1.  Therapeutic efficacy of high-dose intravenous immunoglobulin in Mycobacterium tuberculosis infection in mice.

Authors:  Eleanor Roy; Evangelos Stavropoulos; John Brennan; Stephen Coade; Elena Grigorieva; Barry Walker; Belinda Dagg; Ricardo E Tascon; Douglas B Lowrie; M Joseph Colston; Stephen Jolles
Journal:  Infect Immun       Date:  2005-09       Impact factor: 3.441

2.  Effects of specific antibodies against Streptococcus pneumoniae on pharmacodynamic parameters of beta-lactams in a mouse sepsis model.

Authors:  J Casal; L Aguilar; I Jado; J Yuste; M J Giménez; J Prieto; A Fenoll
Journal:  Antimicrob Agents Chemother       Date:  2002-05       Impact factor: 5.191

3.  Evaluation of a novel therapeutic approach to treating severe pneumococcal infection using a mouse model.

Authors:  Nikkol Melnick; Gowrisankar Rajam; George M Carlone; Jacquelyn S Sampson; Edwin W Ades
Journal:  Clin Vaccine Immunol       Date:  2009-04-22

4.  Clinically relevant model of pneumococcal pneumonia, ARDS, and nonpulmonary organ dysfunction in mice.

Authors:  Jeffrey E Gotts; Olivier Bernard; Lauren Chun; Roxanne H Croze; James T Ross; Nicolas Nesseler; Xueling Wu; Jason Abbott; Xiaohui Fang; Carolyn S Calfee; Michael A Matthay
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2019-09-11       Impact factor: 5.464

5.  Modification of bacteraemia by specific antibodies and relation with mortality in a pneumococcal mouse sepsis model.

Authors:  J Yuste; I Jado; M J Giménez; L Aguilar; F Molero; A Fenoll; J Casal
Journal:  Clin Exp Immunol       Date:  2002-06       Impact factor: 4.330

Review 6.  Invasive pneumococcal disease caused by mucoid serotype 3 Streptococcus pneumoniae: a case report and literature review.

Authors:  Naomi Sugimoto; Yuka Yamagishi; Jun Hirai; Daisuke Sakanashi; Hiroyuki Suematsu; Naoya Nishiyama; Yusuke Koizumi; Hiroshige Mikamo
Journal:  BMC Res Notes       Date:  2017-01-04

7.  Naturally Acquired Human Immunity to Pneumococcus Is Dependent on Antibody to Protein Antigens.

Authors:  Robert Wilson; Jonathan M Cohen; Mark Reglinski; Ricardo J Jose; Win Yan Chan; Helina Marshall; Corné de Vogel; Stephen Gordon; David Goldblatt; Fernanda C Petersen; Helen Baxendale; Jeremy S Brown
Journal:  PLoS Pathog       Date:  2017-01-30       Impact factor: 6.823

Review 8.  Re-evaluation of the therapy of severe pneumonia caused by Streptococcus pneumoniae.

Authors:  Joseph F Plouffe; Daniel R Martin
Journal:  Infect Dis Clin North Am       Date:  2004-12       Impact factor: 5.982

9.  Higher Cytokine and Opsonizing Antibody Production Induced by Bovine Serum Albumin (BSA)-Conjugated Tetrasaccharide Related to Streptococcus pneumoniae Type 3 Capsular Polysaccharide.

Authors:  Ekaterina A Kurbatova; Nelli K Akhmatova; Anton E Zaytsev; Elina A Akhmatova; Nadezhda B Egorova; Natalya E Yastrebova; Elena V Sukhova; Dmitriy V Yashunsky; Yury E Tsvetkov; Nikolay E Nifantiev
Journal:  Front Immunol       Date:  2020-12-04       Impact factor: 7.561

Review 10.  Intravenous immunoglobulin for infectious diseases: back to the pre-antibiotic and passive prophylaxis era?

Authors:  Jagadeesh Bayry; Sébastien Lacroix-Desmazes; Michel D Kazatchkine; Srini V Kaveri
Journal:  Trends Pharmacol Sci       Date:  2004-06       Impact factor: 14.819
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.